Abstract

The CSMI recommends vaccination against shingles with recombinant vaccine with adjuvant (Shingrix®) to prevent the onset of shingles, neuralgia and other post-herpetic complications:

  • For adults aged 65 years and over with 2 doses administered per route intramuscularly spaced 2 to 6 months apart.
  • For adults 18 years of age or older who are or will be immunocompromised due to illness or treatment with 2 doses administered intramuscularly spaced 1 to 2 months apart.
  • Recommendation
  • Europe
  • Luxembourg
  • Older adults (65+)
  • Risk group
  • Herpes zoster